AU2007297042B2 - Treatment of non-Hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin - Google Patents

Treatment of non-Hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin Download PDF

Info

Publication number
AU2007297042B2
AU2007297042B2 AU2007297042A AU2007297042A AU2007297042B2 AU 2007297042 B2 AU2007297042 B2 AU 2007297042B2 AU 2007297042 A AU2007297042 A AU 2007297042A AU 2007297042 A AU2007297042 A AU 2007297042A AU 2007297042 B2 AU2007297042 B2 AU 2007297042B2
Authority
AU
Australia
Prior art keywords
dose
compound
substituted
body surface
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007297042A
Other languages
English (en)
Other versions
AU2007297042A1 (en
Inventor
Puja Sapra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of AU2007297042A1 publication Critical patent/AU2007297042A1/en
Application granted granted Critical
Publication of AU2007297042B2 publication Critical patent/AU2007297042B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2007297042A 2006-09-15 2007-08-17 Treatment of non-Hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin Ceased AU2007297042B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84493806P 2006-09-15 2006-09-15
US60/844,938 2006-09-15
US86451606P 2006-11-06 2006-11-06
US60/864,516 2006-11-06
US11/704,607 2007-02-09
US11/704,607 US7462627B2 (en) 2006-02-09 2007-02-09 Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
PCT/US2007/076241 WO2008033643A2 (en) 2006-09-15 2007-08-17 Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin

Publications (2)

Publication Number Publication Date
AU2007297042A1 AU2007297042A1 (en) 2008-03-20
AU2007297042B2 true AU2007297042B2 (en) 2013-01-10

Family

ID=39184444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007297042A Ceased AU2007297042B2 (en) 2006-09-15 2007-08-17 Treatment of non-Hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin

Country Status (11)

Country Link
US (3) US7462627B2 (US07462627-20081209-C00021.png)
EP (1) EP2073809A4 (US07462627-20081209-C00021.png)
JP (1) JP2010503691A (US07462627-20081209-C00021.png)
KR (2) KR20090059117A (US07462627-20081209-C00021.png)
CN (1) CN101707888B (US07462627-20081209-C00021.png)
AU (1) AU2007297042B2 (US07462627-20081209-C00021.png)
BR (1) BRPI0716807A2 (US07462627-20081209-C00021.png)
CA (1) CA2662920A1 (US07462627-20081209-C00021.png)
IL (1) IL197122A0 (US07462627-20081209-C00021.png)
MX (1) MX2009002853A (US07462627-20081209-C00021.png)
WO (1) WO2008033643A2 (US07462627-20081209-C00021.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2010025337A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
RS59607B1 (sr) * 2008-09-23 2020-01-31 Nektar Therapeutics Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan)
JP2012506380A (ja) * 2008-10-21 2012-03-15 エンゾン ファーマシューティカルズ，インコーポレーテッド ７−エチル−１０−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療
JP2012526049A (ja) * 2009-05-04 2012-10-25 インテザイン テクノロジーズ， インコーポレイテッド 腫瘍治療のためのｓｎ−３８を含有するポリマーミセル
CA2768494A1 (en) * 2009-07-22 2011-01-27 Enzon Pharmaceuticals, Inc. Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2011063156A2 (en) * 2009-11-18 2011-05-26 Nektar Therapeutics Acid salt forms of polymer-drug conjugates and alkoxylation methods
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
TWI716342B (zh) 2013-10-04 2021-01-21 美商普洛林克斯有限責任公司 Sn-38之緩釋結合物
CN104650342B (zh) * 2013-11-18 2018-07-10 江苏豪森药业集团有限公司 多支链聚合药物前体及其应用
CN108727582B (zh) * 2017-04-21 2021-11-05 博瑞生物医药（苏州）股份有限公司 靶向抗癌偶联物
WO2019140271A2 (en) 2018-01-12 2019-07-18 Prolynx Llc Synergistic cancer treatment
CN110577550A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-去甲斑蝥素结合物及其应用
WO2022035843A1 (en) * 2020-08-12 2022-02-17 Nanomedicine Innovation Center, Llc Topoisomerase inhibitors
EP4217007A1 (en) 2020-09-28 2023-08-02 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Peptidic conjugates of sn38 useful in the treatment of cancer
WO2023095741A1 (ja) * 2021-11-25 2023-06-01 日油株式会社 医療用４分岐型水溶性ポリマー
WO2023186822A1 (en) 2022-03-28 2023-10-05 Hospital Sant Joan De Deu Peptidic water-soluble delivery system of anticancer drugs

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
TW438775B (en) * 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH10168373A (ja) * 1996-12-12 1998-06-23 Fuji Xerox Co Ltd インクジェット記録用インク及びそれを用いる記録方法
JP3855344B2 (ja) * 1997-02-19 2006-12-06 日本油脂株式会社 ポリオキシアルキレンカルボン酸の製造方法
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) * 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO2000021370A1 (en) * 1998-10-14 2000-04-20 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
EP1141384A2 (en) * 1999-01-06 2001-10-10 Cornell Research Foundation, Inc. Method for accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6723338B1 (en) * 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2000064486A2 (en) 1999-04-28 2000-11-02 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
PL354623A1 (en) * 1999-10-12 2004-02-09 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
ATE317868T1 (de) * 1999-12-22 2006-03-15 Nektar Therapeutics Al Corp Sterisch gehinderte derivate von wasserlöslichen polymeren
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
WO2001051494A1 (en) * 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2001257577A1 (en) * 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
RU2002128610A (ru) * 2000-03-17 2004-03-27 Селл Терапьютикс, Инк. (Us) Композиция конъюгатов полиглутаминовой кислоты с камптотецином (варианты) и способ ее получения (варианты), фармацевтическая композиция (варианты) и способ лечения лейкоза или плотной опухоли
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6756037B2 (en) * 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US20020182172A1 (en) * 2000-11-30 2002-12-05 Shearwater Corporation Water-soluble polymer conjugates of triazine derivatives
US20020123401A1 (en) * 2001-03-02 2002-09-05 Henry Rassem Ragheb Combination starter-generator
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP4123856B2 (ja) * 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
WO2003033525A1 (en) 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
MXPA04004026A (es) 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
EP1453545B1 (en) 2001-10-30 2007-04-18 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
RU2325156C2 (ru) * 2002-06-06 2008-05-27 Юниверсити Оф Вашингтон Ковалентные конъюгаты между родственными артемизинину эндопероксидами и железосодержащими белками и способы применения
ATE533513T1 (de) * 2002-09-06 2011-12-15 Cerulean Pharma Inc Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
US6649778B1 (en) * 2002-09-20 2003-11-18 Enzon, Inc. Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same
US7879868B2 (en) * 2002-10-11 2011-02-01 Novartis Ag Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
ATE400602T1 (de) 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von hydrogelen aus thiosulfonat-zusammensetzungen und ihre verwendungen
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7744861B2 (en) * 2003-09-17 2010-06-29 Nektar Therapeutics Multi-arm polymer prodrugs
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US20050214250A1 (en) * 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
JP4805911B2 (ja) * 2004-03-15 2011-11-02 ネクター セラピューティクス Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
CA2561111A1 (en) * 2004-03-26 2005-10-13 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
CN101420963B (zh) * 2006-02-09 2012-09-05 安佐制药股份有限公司 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUGIYAMA KATSUKI et al, Cancer, 2002,94(3), 594-600 *

Also Published As

Publication number Publication date
WO2008033643A2 (en) 2008-03-20
EP2073809A2 (en) 2009-07-01
AU2007297042A1 (en) 2008-03-20
KR20090059117A (ko) 2009-06-10
US8299089B2 (en) 2012-10-30
US7462627B2 (en) 2008-12-09
BRPI0716807A2 (pt) 2013-11-05
IL197122A0 (en) 2009-11-18
CN101707888B (zh) 2013-05-15
MX2009002853A (es) 2009-03-27
US20100204261A1 (en) 2010-08-12
CN101707888A (zh) 2010-05-12
CA2662920A1 (en) 2008-03-20
EP2073809A4 (en) 2011-04-13
WO2008033643A3 (en) 2008-12-11
JP2010503691A (ja) 2010-02-04
US20070197575A1 (en) 2007-08-23
KR20150005721A (ko) 2015-01-14
US7723351B2 (en) 2010-05-25
US20090074706A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
AU2007297042B2 (en) Treatment of non-Hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
AU2007212201B2 (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7928095B2 (en) Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2341774B1 (en) Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8048891B2 (en) Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US20100056555A1 (en) Method of treating ras associated cancer
US20090156629A1 (en) Indenoisoquinoline-releasable polymer conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired